rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Ronald Hunt

Director

Company insider

Files Form 4 as: Director, Rallybio; Director and 10% owner, Iterum Therapeutics; Director and 10% owner, Harpoon Therapeutics; Director and 10% owner, Neuronetics; 10% owner, Lite Strategy; Director and 10% owner, Durata Therapeutics; Insider, Relypsa.

Every Form 4 they filed

In numbers

Trades disclosed
137
Buys
8
Sells
4
Bought
$41.7M
Sold
$2.2M
Companies
7
Companies where not an officer
7
First trade
24 Jul 2012
Last trade
18 Feb 2026
Last filed
20 Feb 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
RLYB RallybioDirector · Biotechnology · last 18 Feb 20261 buy · 0 sells
Iterum TherapeuticsDirector, 10% owner · last 13 Jan 20251 buy · 0 sells
Harpoon TherapeuticsDirector, 10% owner · last 11 Mar 20244 buys · 0 sells
STIM NeuroneticsDirector, 10% owner · Medical Devices · last 1 Apr 20190 buys · 0 sells
LITS Lite Strategy10% owner · Biotechnology · last 9 Dec 20140 buys · 4 sells
Durata TherapeuticsDirector, 10% owner · last 21 May 20141 buy · 0 sells
Relypsalast 20 Nov 20131 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
18 Feb 2026filed 20 Feb 2026RLYB Rallybiooption or derivative · BiotechnologySEC FORM 4 Code A$51K14,305 at $3.60filing
18 Feb 2026filed 20 Feb 2026RLYB Rallybiooption or derivative · BiotechnologySEC FORM 4 Code A$51K14,305 at $3.60filing
13 May 2025filed 15 May 2025RLYB Rallybiooption or derivative · BiotechnologySEC FORM 4 Code A—28,500 at $0.00filing
13 Jan 2025filed 23 Jan 2025Iterum Therapeuticsoption or derivativeSEC FORM 4 Code J—filing
13 Jan 2025filed 23 Jan 2025Iterum Therapeuticsoption or derivativeSEC FORM 4 Code J—filing
2 Jan 2025filed 6 Jan 2025RLYB Rallybiooption or derivative · BiotechnologySEC FORM 4 Code A$51K73,571 at $0.70filing
6 Aug 2024filed 12 Aug 2024Iterum Therapeuticsoption or derivativeSEC FORM 4 Code M—364,906 at $0.00filing
6 Aug 2024filed 12 Aug 2024Iterum Therapeuticsoption or derivativeSEC FORM 4 Code M—182,453filing
6 Aug 2024filed 12 Aug 2024Iterum Therapeuticsoption or derivativeSEC FORM 4 Code M—182,453filing
6 Aug 2024filed 12 Aug 2024Iterum Therapeuticsoption or derivativeSEC FORM 4 Code M—130,962 at $0.00filing
6 Aug 2024filed 12 Aug 2024Iterum Therapeuticsoption or derivativeSEC FORM 4 Code M—65,481filing
6 Aug 2024filed 12 Aug 2024Iterum Therapeuticsoption or derivativeSEC FORM 4 Code M—65,481filing
6 Aug 2024filed 12 Aug 2024Iterum TherapeuticsSEC FORM 4 Code M—182,453filing
6 Aug 2024filed 12 Aug 2024Iterum TherapeuticsSEC FORM 4 Code M—65,481filing
15 May 2024filed 17 May 2024RLYB Rallybiooption or derivative · BiotechnologySEC FORM 4 Code A—16,500 at $0.00filing
11 Mar 2024filed 11 Mar 2024Harpoon Therapeuticsoption or derivativeSEC FORM 4 Code D—299,430filing
11 Mar 2024filed 11 Mar 2024Harpoon Therapeuticsoption or derivativeSEC FORM 4 Code D—686,000filing
11 Mar 2024filed 11 Mar 2024Harpoon Therapeuticsoption or derivativeSEC FORM 4 Code D—85,750filing
11 Mar 2024filed 11 Mar 2024Harpoon Therapeuticsoption or derivativeSEC FORM 4 Code D—2,033filing
11 Mar 2024filed 11 Mar 2024Harpoon Therapeuticsoption or derivativeSEC FORM 4 Code D—1,016filing

Sectors

Health Care5
Not placed7

Buys in green, sells in red, by the company’s sector.

Related people

Helen M. BoudreauDirector · Director at Rallybio, filing Form 4 there in the last year
Paula SoteropoulosDirector · Director at Rallybio, filing Form 4 there in the last year
Robert Lorne HopfnerDirector · Director at Rallybio, filing Form 4 there in the last year
Jonathan I. LieberChief Financial Officer · Chief Financial Officer at Rallybio, filing Form 4 there in the last year
Stephen UdenChief Executive Officer · Chief Executive Officer at Rallybio, filing Form 4 there in the last year